Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.

Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, Musolino C, Patriarca F, Musto P, Galieni P, Ballanti S, Nozzoli C, Cascavilla N, Ben-Yehuda D, Nagler A, Hajek R, Offidani M, Liberati AM, Sonneveld P, Cavo M, Corradini P, Boccadoro M.

Haematologica. 2019 Jun 20. pii: haematol.2019.219139. doi: 10.3324/haematol.2019.219139. [Epub ahead of print]

2.

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.

Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, Nagler A, Ozcan M, Avivi I, Bosch F, Caballero Barrigón MD, Hellmann A, Kuss B, Ma DDF, Demirkan F, Yağci M, Horowitz NA, Marlton P, Cordoba R, Wrobel T, Buglio D, Streit M, Hodkinson BP, Schaffer M, Alvarez J, Ceulemans R, Balasubramanian S, de Jong J, Wang SS, Fourneau N, Jurczak W.

Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11.

PMID:
30642819
3.

Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma.

Ledergor G, Weiner A, Zada M, Wang SY, Cohen YC, Gatt ME, Snir N, Magen H, Koren-Michowitz M, Herzog-Tzarfati K, Keren-Shaul H, Bornstein C, Rotkopf R, Yofe I, David E, Yellapantula V, Kay S, Salai M, Ben Yehuda D, Nagler A, Shvidel L, Orr-Urtreger A, Halpern KB, Itzkovitz S, Landgren O, San-Miguel J, Paiva B, Keats JJ, Papaemmanuil E, Avivi I, Barbash GI, Tanay A, Amit I.

Nat Med. 2018 Dec;24(12):1867-1876. doi: 10.1038/s41591-018-0269-2. Epub 2018 Dec 6.

PMID:
30523328
4.

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O, Novak J, Ben-Yehuda D, Strugov V, Gill D, Gribben JG, Hsu E, Lih CJ, Zhou C, Clow F, James DF, Styles L, Flinn IW.

Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10.

PMID:
30522969
5.

American Funding Cutback to East Jerusalem Hospitals: A Blow to the Health of the City.

Clarfield AM, Skorecki K, Paltiel O, Glick SM, Beyar R, Ben Yehuda D, Carmi R, Gil Z, Billan S, Azzam Z, Basis F, Levy-Lahad E, Lahad A, Izraeli S, Turner D, Halevy Y.

Am J Public Health. 2018 Dec;108(12):1624-1625. doi: 10.2105/AJPH.2018.304792. No abstract available.

6.

Serum organochlorines and non-Hodgkin lymphoma: A case-control study in Israeli Jews and Palestinians.

Klil-Drori AJ, Kleinstern G, Seir RA, Choshen-Cohen L, Abdeen Z, Hussein E, Aqel M, Göen T, Perlman R, Ben-Yehuda D, Paltiel O.

Chemosphere. 2018 Dec;213:395-402. doi: 10.1016/j.chemosphere.2018.09.069. Epub 2018 Sep 14.

PMID:
30241084
7.

Early hydrocephalus in Listeria meningitis: Case report and review of the literature.

Nachmias B, Orenbuch-Harroch E, Makranz C, Nechusthan H, Eliahou R, Ben-Yehuda D, Lossos A.

IDCases. 2018 Sep 5;14:e00455. doi: 10.1016/j.idcr.2018.e00455. eCollection 2018.

8.

Digital Workflow: From Guided Surgery to Final Full-Arch Implant Prosthesis in Three Visits.

Papaspyridakos P, Ben Yehuda D, Rajput N, Weber HP.

Compend Contin Educ Dent. 2018 Jul/Aug;39(7):e1-e4.

PMID:
30020795
9.

The oncogenic fusion protein CBFB-SMMHC downregulates CD48 to evade NK cell recognition.

Kahlon S, Shreibman D, Unger T, Ben-Yehuda D, Elias S.

Blood Cancer J. 2018 May 24;8(5):48. doi: 10.1038/s41408-018-0082-7. No abstract available.

10.

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.

Trnĕný M, Verhoef G, Dyer MJ, Ben Yehuda D, Patti C, Canales M, Lopez A, Awan FT, Montgomery PG, Janikova A, Barbui AM, Sulek K, Terol MJ, Radford J, Guidetti A, Di Nicola M, Siraudin L, Hatteville L, Schwab S, Oprea C, Gianni AM.

Haematologica. 2018 Aug;103(8):1351-1358. doi: 10.3324/haematol.2017.168401. Epub 2018 May 10.

11.

Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.

Cerrato C, Di Raimondo F, De Paoli L, Spada S, Patriarca F, Crippa C, Mina R, Guglielmelli T, Ben-Yehuda D, Oddolo D, Nozzoli C, Angelucci E, Cascavilla N, Rizzi R, Rocco S, Baldini L, Ponticelli E, Marcatti M, Cangialosi C, Caravita T, Benevolo G, Ria R, Nagler A, Musto P, Tacchetti P, Corradini P, Offidani M, Palumbo A, Petrucci MT, Boccadoro M, Gay F.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1357-1366. doi: 10.1007/s00432-018-2641-5. Epub 2018 Apr 19.

PMID:
29675792
12.

Presence of autoimmune disease affects not only risk but also survival in patients with B-cell non-Hodgkin lymphoma.

Kleinstern G, Averbuch M, Abu Seir R, Perlman R, Ben Yehuda D, Paltiel O.

Hematol Oncol. 2018 Apr;36(2):457-462. doi: 10.1002/hon.2498. Epub 2018 Feb 22.

PMID:
29469175
13.

Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.

Pick M, Vainstein V, Goldschmidt N, Lavie D, Libster D, Gural A, Grisariu S, Avni B, Ben Yehuda D, Gatt ME.

Eur J Haematol. 2018 May;100(5):494-501. doi: 10.1111/ejh.13046. Epub 2018 Mar 25.

PMID:
29453884
14.

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG.

Blood. 2017 Dec 14;130(24):2610-2618. doi: 10.1182/blood-2017-06-791228. Epub 2017 Oct 20.

15.

Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.

Dann EJ, Bairey O, Bar-Shalom R, Mashiach T, Barzilai E, Kornberg A, Akria L, Tadmor T, Filanovsky K, Abadi U, Kagna O, Ruchlemer R, Abdah-Bortnyak R, Goldschmidt N, Epelbaum R, Horowitz NA, Lavie D, Ben-Yehuda D, Shpilberg O, Paltiel O.

Br J Haematol. 2017 Sep;178(5):709-718. doi: 10.1111/bjh.14734. Epub 2017 Jun 7.

PMID:
28589704
16.

Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia.

Abramowitz J, Neuman T, Perlman R, Ben-Yehuda D.

BMC Med Genomics. 2017 Mar 24;10(1):18. doi: 10.1186/s12920-017-0249-2.

17.

Ethnic variation in medical and lifestyle risk factors for B cell non-Hodgkin lymphoma: A case-control study among Israelis and Palestinians.

Kleinstern G, Abu Seir R, Perlman R, Khatib A, Abdeen Z, Elyan H, Nirel R, Amir G, Ramlawi A, Sabatin F, Boffetta P, Dann EJ, Kedmi M, Ellis M, Nagler A, Ben Yehuda D, Paltiel O.

PLoS One. 2017 Feb 14;12(2):e0171709. doi: 10.1371/journal.pone.0171709. eCollection 2017.

18.

The JAK2V617F mutation in normal individuals takes place in differentiating cells.

Krichevsky S, Prus E, Perlman R, Fibach E, Ben-Yehuda D.

Blood Cells Mol Dis. 2017 Mar;63:45-51. doi: 10.1016/j.bcmd.2017.01.001. Epub 2017 Jan 7.

PMID:
28126623
19.

The prognostic value of bone marrow involvement at the molecular level in aggressive lymphoma.

Goldschmidt N, Darawshy F, Kleinstern G, Slyusarevsky E, Pogrebijski G, Krichevsky S, Ben-Yehuda D, Gatt ME.

Leuk Lymphoma. 2017 Jan;58(1):45-52. Epub 2016 Oct 18.

PMID:
27756163
20.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators.

N Engl J Med. 2016 Oct 6;375(14):1319-1331.

21.

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P.

Blood. 2016 Sep 1;128(9):1174-80. doi: 10.1182/blood-2016-03-707596. Epub 2016 Jul 20.

22.

Hypersensitivity reactions to rituximab: 53 successful desensitizations in 7 patients with severe, near-fatal reactions.

Lebel E, Ben-Yehuda D, Bohbot E, Dranitzki Z, Shalit M, Tal Y.

J Allergy Clin Immunol Pract. 2016 Sep-Oct;4(5):1000-2. doi: 10.1016/j.jaip.2016.05.013. Epub 2016 Jun 18. No abstract available.

PMID:
27329468
23.

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

Moreau P, van de Donk NW, Miguel JS, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Einsele H, Zweegman S, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Mateos MV.

Drugs. 2016 Jun;76(9):989-990. No abstract available.

PMID:
27206917
24.

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

Moreau P, van de Donk NW, San Miguel J, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Einsele H, Zweegman S, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Mateos MV.

Drugs. 2016 May;76(8):853-67. doi: 10.1007/s40265-016-0573-4. Review. Erratum in: Drugs. 2016 Jun;76(9):989-90.

PMID:
27113582
25.

Associations between B-cell non-Hodgkin lymphoma and exposure, persistence and immune response to hepatitis B.

Kleinstern G, Seir RA, Perlman R, Abdeen Z, Khatib A, Elyan H, Dann EJ, Kedmi M, Ellis M, Nagler A, Amir G, Ben Yehuda D, Safadi R, Paltiel O.

Haematologica. 2016 Jul;101(7):e303-5. doi: 10.3324/haematol.2016.144840. Epub 2016 Apr 21. No abstract available.

26.

Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy.

Goldschmidt N, Kleinstern G, Orevi M, Paltiel O, Ben-Yehuda D, Gural A, Libster D, Lavie D, Gatt ME.

Cancer Chemother Pharmacol. 2016 May;77(5):1053-60. doi: 10.1007/s00280-016-3024-8. Epub 2016 Apr 7.

PMID:
27056383
27.

Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.

Jaeger U, Trneny M, Melzer H, Praxmarer M, Nawarawong W, Ben Yehuda D, Goldstein D, Mihaljevic B, Ilhan O, Ballova V, Hedenus M, Hsiao LT, Au WY, Burgstaller S, Weidinger G, Keil F, Dittrich C, Skrabs C, Klingler A, Chott A, Fridrik MA, Greil R; AGMT-NHL13 Investigators.

Haematologica. 2015 Jul;100(7):955-63. doi: 10.3324/haematol.2015.125344. Epub 2015 Apr 24.

28.

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators.

N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6.

29.

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.

Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B.

Br J Haematol. 2015 Mar;168(6):811-9. doi: 10.1111/bjh.13222. Epub 2014 Nov 17.

PMID:
25404094
30.

Autologous transplantation and maintenance therapy in multiple myeloma.

Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omedé P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M.

N Engl J Med. 2014 Sep 4;371(10):895-905. doi: 10.1056/NEJMoa1402888.

31.

Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression.

Oki Y, Buglio D, Zhang J, Ying Y, Zhou S, Sureda A, Ben-Yehuda D, Zinzani PL, Prince HM, Harrison SJ, Kirschbaum M, Johnston PB, Shen A, von Tresckow B, Younes A.

Blood Cancer J. 2014 Aug 8;4:e236. doi: 10.1038/bcj.2014.58. No abstract available.

32.

Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma.

Rendleman J, Antipin Y, Reva B, Adaniel C, Przybylo JA, Dutra-Clarke A, Hansen N, Heguy A, Huberman K, Borsu L, Paltiel O, Ben-Yehuda D, Brown JR, Freedman AS, Sander C, Zelenetz A, Klein RJ, Shao Y, Lacher M, Vijai J, Offit K, Kirchhoff T.

PLoS One. 2014 Jul 10;9(7):e101685. doi: 10.1371/journal.pone.0101685. eCollection 2014.

33.

tLivin displays flexibility by promoting alternative cell death mechanisms.

Shiloach T, Berens C, Danke C, Waiskopf O, Perlman R, Ben-Yehuda D.

PLoS One. 2014 Jun 24;9(6):e101075. doi: 10.1371/journal.pone.0101075. eCollection 2014.

34.

Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.

Vine J, Cohen SB, Ruchlemer R, Goldschmidt N, Levin M, Libster D, Gural A, Gatt ME, Lavie D, Ben-Yehuda D, Rund D.

Leuk Lymphoma. 2014 Nov;55(11):2525-31. doi: 10.3109/10428194.2014.893307. Epub 2014 Mar 19.

PMID:
24524306
35.

Immune evasion by oncogenic proteins of acute myeloid leukemia.

Elias S, Yamin R, Golomb L, Tsukerman P, Stanietsky-Kaynan N, Ben-Yehuda D, Mandelboim O.

Blood. 2014 Mar 6;123(10):1535-43. doi: 10.1182/blood-2013-09-526590. Epub 2014 Jan 21.

36.

Differential regulation of the apoptotic machinery during megakaryocyte differentiation and platelet production by inhibitor of apoptosis protein Livin.

Abd-Elrahman I, Deutsch V, Pick M, Kay S, Neuman T, Perlman R, Ben-Yehuda D.

Cell Death Dis. 2013 Nov 28;4:e937. doi: 10.1038/cddis.2013.454.

37.

International Myeloma Working Group recommendations for global myeloma care.

Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia Sanz R, Powles R, Lentzsch S, Ming Chen W, Hou J, Jurczyszyn A, Romeril K, Hajek R, Terpos E, Shimizu K, Joshua D, Hungria V, Rodriguez Morales A, Ben-Yehuda D, Sondergeld P, Zamagni E, Durie B.

Leukemia. 2014 May;28(5):981-92. doi: 10.1038/leu.2013.293. Epub 2013 Oct 9. Review.

PMID:
24177258
38.

Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma.

Azoulay D, Lavie D, Horowitz N, Suriu C, Gatt ME, Akria L, Perlman R, Braester A, Ben-Yehuda D.

Br J Haematol. 2014 Feb;164(3):454-6. doi: 10.1111/bjh.12624. Epub 2013 Oct 25. No abstract available.

PMID:
24164472
39.

Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia.

Goldschmidt N, Gural A, Ben-Yehuda D, Gatt ME.

Cancer Chemother Pharmacol. 2013 Sep;72(3):709-13. doi: 10.1007/s00280-013-2243-5. Epub 2013 Aug 2.

PMID:
23907444
40.

Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies.

Vijai J, Kirchhoff T, Schrader KA, Brown J, Dutra-Clarke AV, Manschreck C, Hansen N, Rau-Murthy R, Sarrel K, Przybylo J, Shah S, Cheguri S, Stadler Z, Zhang L, Paltiel O, Ben-Yehuda D, Viale A, Portlock C, Straus D, Lipkin SM, Lacher M, Robson M, Klein RJ, Zelenetz A, Offit K.

PLoS Genet. 2013;9(1):e1003220. doi: 10.1371/journal.pgen.1003220. Epub 2013 Jan 17.

41.

High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.

O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, Ben-Yehuda D, Stock W, Coutre S, Douer D, Heffner LT, Larson M, Seiter K, Smith S, Assouline S, Kuriakose P, Maness L, Nagler A, Rowe J, Schaich M, Shpilberg O, Yee K, Schmieder G, Silverman JA, Thomas D, Deitcher SR, Kantarjian H.

J Clin Oncol. 2013 Feb 20;31(6):676-83. doi: 10.1200/JCO.2012.46.2309. Epub 2012 Nov 19.

42.

Extracellular matrix constituents interfere with Newcastle disease virus spread in solid tissue and diminish its potential oncolytic activity.

Yaacov B, Lazar I, Tayeb S, Frank S, Izhar U, Lotem M, Perlman R, Ben-Yehuda D, Zakay-Rones Z, Panet A.

J Gen Virol. 2012 Aug;93(Pt 8):1664-72. doi: 10.1099/vir.0.043281-0. Epub 2012 May 23.

PMID:
22622327
43.

Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015 Investigators.

N Engl J Med. 2012 May 10;366(19):1759-69. doi: 10.1056/NEJMoa1112704. Erratum in: N Engl J Med. 2012 Jul 19;367(3):285.

44.

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, Harrison SJ, Kirschbaum M, Johnston P, Gallagher J, Le Corre C, Shen A, Engert A.

J Clin Oncol. 2012 Jun 20;30(18):2197-203. doi: 10.1200/JCO.2011.38.1350. Epub 2012 Apr 30.

PMID:
22547596
45.

The clinical effect of the inhibitor of apopotosis protein livin in melanoma.

Lazar I, Perlman R, Lotem M, Peretz T, Ben-Yehuda D, Kadouri L.

Oncology. 2012;82(4):197-204. doi: 10.1159/000334234. Epub 2012 Mar 22.

PMID:
22441029
46.

High incidence of skin rash in patients with hairy cell leukemia treated with cladribine.

Ganzel C, Gatt ME, Maly A, Ben-Yehuda D, Goldschmidt N.

Leuk Lymphoma. 2012 Jun;53(6):1169-73. doi: 10.3109/10428194.2011.635864. Epub 2011 Dec 7.

PMID:
22035415
47.

Janus Kinase V617F mutation in cigarette smokers.

Weinberg I, Borohovitz A, Krichevsky S, Perlman R, Ben-Yehuda A, Ben-Yehuda D.

Am J Hematol. 2012 Jan;87(1):5-8. doi: 10.1002/ajh.22180. Epub 2011 Sep 26.

48.

Clinical implications of acute myeloid leukemia presenting as myeloid sarcoma.

Avni B, Rund D, Levin M, Grisariu S, Ben-Yehuda D, Bar-Cohen S, Paltiel O.

Hematol Oncol. 2012 Mar;30(1):34-40. doi: 10.1002/hon.994. Epub 2011 Jun 2.

PMID:
21638303
49.

Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy.

Cavallo F, Bringhen S, Milone G, Ben-Yehuda D, Nagler A, Calabrese E, Cascavilla N, Montefusco V, Lupo B, Liberati AM, Crippa C, Rossini F, Passera R, Patriarca F, Cafro AM, Omedè P, Carella AM, Peccatori J, Catalano L, Caravita T, Musto P, Petrucci MT, Boccadoro M, Palumbo A.

Leukemia. 2011 Oct;25(10):1627-31. doi: 10.1038/leu.2011.131. Epub 2011 Jun 3.

PMID:
21637283
50.

Autologous stem cell transplantation in a rare multicentric Castleman disease of the plasma cell variant.

Tal Y, Haber G, Cohen MJ, Phillips M, Amir G, Ben-Yehuda D, Ben-Yehuda A.

Int J Hematol. 2011 May;93(5):677-680. doi: 10.1007/s12185-011-0812-0. Epub 2011 Mar 26.

PMID:
21437636

Supplemental Content

Loading ...
Support Center